pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Sword Health to acquire mental-health platform Headspace in cash deal slated for September 14

Aug 25, 2026·read at STAT ↗DealNeutral

Sword Health, a digital health firm best known for its AI‑driven virtual physical therapy, has filed to purchase mental‑health service provider Headspace.

The regulatory filing indicates the transaction will close on September 14, with Sword paying cash; the purchase price was not disclosed. Headspace’s parent, OrangeDot, reported the material change to the Massachusetts Health Policy Commission.

Sword Health last raised $40 million in 2025, valuing the company at over $4 billion, and has accumulated roughly $493 million in total funding, underscoring its strategy to broaden its platform into mental‑health offerings.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Sword Health to acquire Headspace, according to filing”

read at STAT ↗
530 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
TEVA PHARMACEUTICAL INDUSTRIES LTD
topics
Psychiatry & CNS5

related stories

  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27What’s the true risk for eating disorders with GLP-1s?STAT
  • Apr 27STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialSTAT
  • Apr 27STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage studySTAT
  • Apr 27STAT+: Veradermics’ hair loss drug succeeds in late-stage trialSTAT